Complexities of adjuvant endocrine therapy in young premenopausal women.
Overall, this excellent overview of management issues for breast cancer patients under 40 years of age highlights the major questions surrounding choices of adjuvant systemic therapy. Treatment choices are dependent on breast cancer biology (receptor status) as well as patient factors (ovarian function and desire for future fertility). As many unanswered questions remain, it is important to continue to enroll subjects in clinical trials focused on this important patient population.
Henry
N Lynn
NL
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, Michigan, USA.
Griggs
Jennifer J
JJ
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D005260:Female; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D010053:Ovary / Q000187:drug effects; D017697:Premenopause; D020845:Selective Estrogen Receptor Modulators / Q000378:metabolism / Q000627:therapeutic use*; D013629:Tamoxifen / Q000378:metabolism / Q000627:therapeutic use*
D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6